 |
|
Investors and CollaboratorsMesophotonics completed its first round financing in July 2001 by securing £2.4 million from BTG. Second round funding of £5.5 million was completed in December 2003. Quester led the investment with participating investors Auriga Partners (Paris), NIF Ventures Co. Ltd (Tokyo) and existing investor BTG. About QuesterQuester is one of the UK's leading independent venture capital groups specialising in the provision of finance and management support for growth companies at all stages of their life. Quester’s focus is on early stage investments in information and communication technology, healthcare and life science companies. With its first rate track record, Quester has earned a reputation as one of the best UK based sources of venture capital. The Quester investment team manages approximately £300 million on behalf of major institutional investors, leading UK universities, and five quoted venture capital trusts. For further information please refer to www.quester.co.uk About AurigaAuriga Partners is a French independent early stage VC fund. Auriga focuses on investments in high potential innovative start ups in the areas of Life Sciences and Information Technology, mainly in Europe. To date Auriga manages about €200M funds split between 3 funds: European Medical Ventures, Auriga Ventures I and Auriga Ventures II. For further information please refer to www.aurigapartners.com About BTGBTG finds, develops and commercialises emerging technologies in the life and physical sciences. These innovations are protected by a strong portfolio of intellectual property that BTG develops and enhances. BTG then captures the value in these technologies through licensing and venturing activities. From the origins of its business in 1949, BTG has commercialised major innovations such as Magnetic Resonance Imaging (MRI), recombinant factor IX blood-clotting protein, Campath® (alemtuzumab) and Multilevel Cell (MLC) memory. BTG is quoted on the London Stock Exchange under the symbol “BGC” and operates from offices in London and Philadelphia, with representation in Tokyo. BTG operates through wholly owned subsidiaries, BTG International Ltd. and BTG International Inc. in the UK and USA, respectively. Further information on BTG can be found at www.btgplc.com About NIFNIF Ventures Co Ltd is the venture capital arm of the Daiwa Securities Group of Japan. NIF manages approximately $1 billion in venture capital funds and has funded over 1,500 companies and assisted over 450 companies to exit since its foundation in 1982. Its primary focus is in information and communications technologies and life science VC investments. With offices in Japan, Taiwan, Singapore, and the United States, NIF offers worldwide representation. Further information on NIF can be found at www.nif.co.jp About The University of SouthamptonThe University of Southampton is a leading UK teaching and research institution with a global reputation for leading-edge research and scholarship. The University, which celebrated its Golden Jubilee in 2002, has 20,000 students and over 4,500 staff and plays an important role in the City of Southampton. Its annual turnover is in the region of £235 million.($425 million). Further information can be found at : www.soton.ac.uk |
||||